The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Open accessAbstract
Currently available HIV-1 protease inhibitors are potent agents in the therapy of HIV-1 infection. However, limited oral absorption and variable tissue distribution, both of which are largely unexplained, complicate their use. We tested the hypothesis that P-glycoprotein is an important transporter for these agents. We studied the vectorial transport characteristics of indinavir, nelfinavir, and saquinavir in vitro using the model P-glycoprotein expressing cell lines L-MDR1 and Caco-2 cells, and in vivo after intravenous and oral administration of these agents to mice with a disrupted mdr1a gene. All three compounds were found to be transported by P-glycoprotein in vitro. After oral administration, plasma concentrations were elevated 2-5-fold in mdr1a (-/-) mice and with intravenous administration, brain concentrations were elevated 7-36-fold. These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain. This raises the possibility that higher HIV-1 protease inhibitor concentrations may be obtained by targeted pharmacologic inhibition of P-glycoprotein transport activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341602 · Cited by 745
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Carpenter, C. C. J. (1996) · JAMA · doi:10.1001/jama.276.2.146 · Cited by 541
Antiretroviral Therapy for HIV Infection: A Knowledge-Based Approach to Drug Selection and Use
Moyle, G. J., Gazzard, B. G., Cooper, D. A., & Gatell, J. (1998) · Drugs · doi:10.2165/00003495-199855030-00005 · Cited by 536
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications
Meunier, V., Bourri�, M., Berger, Y., & Fabre, G. (1995) · Cell Biology and Toxicology · doi:10.1007/bf00756522 · Cited by 434
HIV-1 Protease Inhibitors: A Review for Clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.1997.03540260059037 · Cited by 434
Bagasra, O., Lavi, E., Bobroski, L., Khalili, K., Pestaner, J. P., Tawadros, R., & Pomerantz, R. J. (1996) · AIDS · doi:10.1097/00002030-199606000-00002 · Cited by 417
P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells
Tsuji, A., Terasaki, T., Takabatake, Y., Tenda, Y., Tamai, I., Yamashima, T., Moritani, S., Tsuruo, T., & Yamashita, J. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90537-y · Cited by 282
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
Craig, J. C., Duncan, I. B., Hockley, D., Grief, C., Roberts, N. A., & Mills, J. S. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90045-s · Cited by 189
Interaction of structurally diverse pesticides with thehuman MDR1 gene product P-glycoprotein
Bain, L. J., & LeBlanc, G. A. (1996) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(96)80035-4 · Cited by 175
A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
Stein, D. S., Fish, D. G., Bilello, J. A., Preston, S. L., Martineau, G. L., & Drusano, G. L. (1996) · AIDS · doi:10.1097/00002030-199605000-00006 · Cited by 172
Ford, J. M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00047-0 · Cited by 164
Lucia, M. B., Cauda, R., LANDAY, A. L., Malorni, W., Donelli, G., & Ortona, L. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.893 · Cited by 50
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Self-citation
Metadata
- Authors
- Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-01-15
- Volume
- 101
- Issue
- 2
- Pages
- 289-294
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2131403498
- Cited by
- 1,054
- References
- 23
- FWCI
- 33.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.